CG
CRSP icon

Cutler Group’s CRISPR Therapeutics CRSP Stock Holding History

Cutler Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-19,700
Closed -$12K – 4511
2022
Q3 		$12K Sell
19,700
-8,700
-31% -$630K ﹤0.01% 2972
2022
Q2 		$41K Buy
28,400
+6,600
+30% +$388K ﹤0.01% 2089
2022
Q1 		$22K Sell
21,800
-25,500
-54% -$1.6M ﹤0.01% 2955
2021
Q4 		$87K Buy
47,300
+25,600
+118% +$2.24M ﹤0.01% 1954
2021
Q3 		$199K Sell
21,700
-1,300
-6% -$163K 0.01% 1366
2021
Q2 		$721K Sell
23,000
-6,300
-22% -$766K 0.03% 592
2021
Q1 		$521K Buy
29,300
+16,300
+125% +$2.46M 0.03% 710
2020
Q4 		$695K Buy
13,000
+9,700
+294% +$1.15M 0.03% 511
2020
Q3 		$31K Sell
3,300
-11,000
-77% -$976K ﹤0.01% 2124
2020
Q2 		$135K Buy
14,300
+13,100
+1,092% +$766K 0.01% 1107
2020
Q1 		$2K Buy
1,200
+900
+300% +$46.5K ﹤0.01% 3450
2019
Q4 		$3K Buy
+300
New +$16.4K ﹤0.01% 3251
2018
Q4 		– Sell
-4,100
Closed -$11K – 4024
2018
Q3 		$11K Sell
4,100
-12,500
-75% -$655K ﹤0.01% 2586
2018
Q2 		$149K Buy
16,600
+13,300
+403% +$758K 0.01% 916
2018
Q1 		$38K Buy
3,300
+400
+14% +$16.5K ﹤0.01% 1850
2017
Q4 		$12K Sell
2,900
-28,100
-91% -$534K ﹤0.01% 2968
2017
Q3 		$27K Buy
+31,000
New +$562K ﹤0.01% 2834

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutler Group's CRSP Position: Q1 2024 in Review

Cutler Group increased its CRISPR Therapeutics (CRSP) stake by 250% in Q1 2024, buying an estimated $35.8K and bringing the position to 700 shares worth $47K. The position accounts for 0.02% of the portfolio, ranked #699.

Cutler Group first reported a position in CRSP in Q2 2017 and has held it in 19 quarters since. The position peaked at $1.95M in Q4 2020. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Cutler Group held 700 shares of CRISPR Therapeutics worth $47K as of Q1 2024.
  • Cutler Group bought 500 CRISPR Therapeutics shares in Q1 2024, an estimated $35.8K.
  • CRISPR Therapeutics made up 0.02% of Cutler Group's portfolio in Q1 2024, its #699 holding.
  • Cutler Group first reported a position in CRISPR Therapeutics in Q2 2017 and has held it in 19 quarters since.
  • Cutler Group's CRISPR Therapeutics position peaked at $1.95M in Q4 2020.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.